1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
US-9545404-B2 · Jan 17, 2017 · US
1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
US10195196B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10195196-B2 |
| Application number | US-201615364248-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 29, 2016 |
| Priority date | Aug 13, 2012 |
| Publication date | Feb 5, 2019 |
| Grant date | Feb 5, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
First claim
Opening claim text (preview).
What is claimed is: 1. A method to treat spinal muscular atrophy Type I comprising administering to a subject in need of treatment thereof an effective amount of the compound according to the following formula or a pharmaceutically acceptable salt thereof. 2. A method to treat spinal muscular atrophy Type II comprising administering to a subject in need of treatment thereof an effective amount of the compound according to the following formula or a pharmaceutically acceptable salt thereof. 3. A method to treat spinal muscular atrophy Type III comprising administering to a subject in need of treatment thereof an effective amount of the compound according to the following formula or a pharmaceutically acceptable salt thereof. 4. A method to treat spinal muscular atrophy Type IV comprising administering to a subject in need of treatment thereof an effective amount of the compound according to the following formula or a pharmaceutically acceptable salt thereof. 5. A compound which is 5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6- tetramethylpiperidin-4-yl)oxy)pyridazin-3-yl)phenol hydrochloride salt. 6. A method to treat spinal muscular atrophy Type I comprising administering to a subject in need of treatment thereof an effective amount of the compound according claim 5 . 7. A method to treat spinal muscular atrophy Type II comprising administering to a subject in need of treatment thereof an effective amount of the compound according claim 5 . 8. A method to treat spinal muscular atrophy Type III comprising administering to a subject in need of treatment thereof an effective amount of the compound according claim 5 . 9. A method to treat spinal muscular atrophy Type IV comprising administering to a subject in need of treatment thereof an effective amount of the compound according claim 5 .
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for disorders of the muscular or neuromuscular system · CPC title
containing three or more hetero rings · CPC title
ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine · CPC title
- C07D401/12Primary
linked by a chain containing hetero atoms as chain links · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10195196B2 cover?
- The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
- Who is the assignee on this patent?
- Novartis Ag
- What technology area does this patent fall under?
- Primary CPC classification C07D401/12. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).